** Shares of telehealth firm Hims & Hers HIMS.N fall 9% to $37.2 premarket
** A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's LLY.N popular weight-loss drug Zepbound in the U.S
** The Outsourcing Facilities Association in October filed a lawsuit against the FDA over its decision to remove the drugs its shortage list, saying that it still remains in short supply
** HIMS sells compounded versions of Novo Nordisk's NOVOb.CO Wegovy and Ozempic, chemically known as semaglutide
** The ruling has "direct read-through to the pending semaglutide case which we also expect will go in the FDA's favor," says brokerage Citi
** HIMS shares have nearly tripled in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。